Remitting multiple sclerosis: Natalizumab reduces relapses and disability
Taking the new generation anti-inflammatory drug natalizumab for two years lowers the number of remitting multiple sclerosis patients who experience relapses and progression of disability. This is the main finding of a systematic ...
Oct 5, 2011
0
0